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Surgical versus Nonsurgical Treatment
for Lumbar Degenerative Spondylolisthesis
James N. Weinstein, D.O., Jon D. Lurie, M.D., Tor D. Tosteson, Sc.D.,
Brett Hanscom, M.S., Anna N.A. Tosteson, Sc.D., Emily A. Blood, M.S.,
Nancy J.O. Birkmeyer, Ph.D., Alan S. Hilibrand, M.D., Harry Herkowitz, M.D.,
Frank P. Cammisa, M.D., Todd J. Albert, M.D., Sanford E. Emery, M.D., M.B.A.,
Lawrence G. Lenke, M.D., William A. Abdu, M.D., Michael Longley, M.D.,
Thomas J. Errico, M.D., and Serena S. Hu, M.D.*

A BS T R AC T
BACKGROUND

Management of degenerative spondylolisthesis with spinal stenosis is controversial.
Surgery is widely used, but its effectiveness in comparison with that of nonsurgical
treatment has not been demonstrated in controlled trials.
METHODS

Surgical candidates from 13 centers in 11 U.S. states who had at least 12 weeks of
symptoms and image-confirmed degenerative spondylolisthesis were offered enrollment in a randomized cohort or an observational cohort. Treatment was standard decompressive laminectomy (with or without fusion) or usual nonsurgical care.
The primary outcome measures were the Medical Outcomes Study 36-Item ShortForm General Health Survey (SF-36) bodily pain and physical function scores (100point scales, with higher scores indicating less severe symptoms) and the modified
Oswestry Disability Index (100-point scale, with lower scores indicating less severe
symptoms) at 6 weeks, 3 months, 6 months, 1 year, and 2 years.
RESULTS

We enrolled 304 patients in the randomized cohort and 303 in the observational cohort. The baseline characteristics of the two cohorts were similar. The one-year crossover rates were high in the randomized cohort (approximately 40% in each direction)
but moderate in the observational cohort (17% crossover to surgery and 3% crossover
to nonsurgical care). The intention-to-treat analysis for the randomized cohort showed
no statistically significant effects for the primary outcomes. The as-treated analysis
for both cohorts combined showed a significant advantage for surgery at 3 months
that increased at 1 year and diminished only slightly at 2 years. The treatment effects
at 2 years were 18.1 for bodily pain (95% confidence interval [CI], 14.5 to 21.7), 18.3
for physical function (95% CI, 14.6 to 21.9), and −16.7 for the Oswestry Disability Index
(95% CI, −19.5 to −13.9). There was little evidence of harm from either treatment.
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CONCLUSIONS

In nonrandomized as-treated comparisons with careful control for potentially confounding baseline factors, patients with degenerative spondylolisthesis and spinal
stenosis treated surgically showed substantially greater improvement in pain and function during a period of 2 years than patients treated nonsurgically. (ClinicalTrials.
gov number, NCT00000409.)
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egenerative spondylolisthesis is
the slipping forward of one lumbar vertebra on another with an intact neural arch.
It rarely occurs before the age of 50 years, and it
disproportionately affects women, particularly
black women, with a male:female ratio of approximately 1:6.1 Slippage most commonly occurs at
the L4–L5 level and rarely exceeds 30% of vertebral width.1 Degenerative spondylolisthesis is generally asymptomatic, but it can be associated with
symptomatic spinal stenosis.1
Spinal stenosis, the most common reason for
lumbar surgery in adults over the age of 65, is a
narrowing of the spinal canal with encroachment
on the neural structures by surrounding bone and
soft tissue. Patients typically present with neurogenic claudication — pain in the buttocks or legs
with walking or standing that resolves with sitting
or lumbar flexion. However, anatomical spinal
stenosis is frequently detected by imaging studies
in asymptomatic patients; thus, clinical correlation
between symptoms and imaging is critical.2
Two studies have compared surgery with nonsurgical treatment for spinal stenosis, but both of
these studies included patients with and those
without degenerative spondylolisthesis.3-5 Several
studies have compared surgical techniques in cohorts with degenerative spondylolisthesis; however, these studies had small samples with limited
geographic participation and lacked nonsurgical
controls and validated outcome measures.6-8 The
optimal treatment strategy for symptomatic degenerative spondylolisthesis remains unclear.
The Spine Patient Outcomes Research Trial
(SPORT) was designed to compare the effectiveness of surgical and nonsurgical treatment among
participants with confirmed diagnoses of intervertebral disk herniation,9,10 spinal stenosis, and
degenerative spondylolisthesis.11 Here we report
the 2-year outcomes of patients with degenerative
spondylolisthesis.
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at each participating institution, and an independent data and safety monitoring board monitored
the results of the trial. The principal investigator
had full access to all the data in the study and takes
responsibility for the accuracy and integrity of the
data analysis. Additional background information
has been published previously.9-11,13
Patient Population

All patients had neurogenic claudication or radicular leg pain with associated neurologic signs, spinal stenosis shown on cross-sectional imaging,
and degenerative spondylolisthesis shown on lateral radiographs obtained with the patient in a
standing position. The patients had had persistent
symptoms for at least 12 weeks and had been confirmed as surgical candidates by their physicians.
Patients with adjacent levels of stenosis were eligible; patients with spondylolysis and isthmic
spondylolisthesis were not. The nature of nonsurgical care before enrollment was not prespecified but included physical therapy in 68% of patients, epidural injections in 55%, chiropractic
treatment in 25%, antiinflammatory agents in
63%, and opioid analgesic agents in 30%.
Research nurses at each site identified potential participants and verified their eligibility. The
patients were offered enrollment in either cohort
and gave written informed consent after viewing
videotapes explaining the expected benefits, risks,
and uncertainties of the treatments.14,15 Participants in the randomized cohort received computergenerated random treatment assignments blocked
according to center; those in the observational
cohort chose their treatment with their physician.
Enrollment began in March 2000 and ended in
February 2005.
Study Interventions

The protocol surgery consisted of a standard posterior decompressive laminectomy with or without bilateral single-level fusion (iliac crest bone
grafting with or without posterior pedicle-screw
Me thods
instrumentation).11 The nonsurgical protocol was
Study Design
usual care, recommended to include at least active
The SPORT was conducted in 11 states at 13 med- physical therapy, education or counseling includical centers in the United States that have multi- ing instructions for exercising at home, and nondisciplinary spine practices. The SPORT included steroidal antiinflammatory agents if tolerated.11,13
both a randomized cohort and a concurrent observational cohort with identical selection criteria and Study Measures
outcomes assessment.12 The standardized proto- The primary end points were the Medical Outcomes
col was approved by human subjects committees Study 36-Item Short-Form General Health Survey
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(SF-36) bodily pain and physical function scores16-19
and the Oswestry Disability Index (American Academy of Orthopaedic Surgeons/Modems version)20
measured at 6 weeks and at 3, 6, 12, and 24 months
after enrollment. Secondary outcomes included
patient-reported improvement, satisfaction with
current symptoms and care,21 the Stenosis Bother
someness Index,22,23 and the Low Back Pain
Bothersomeness Scale.3 The SF-36 scores range
from 0 to 100, with higher scores indicating less
severe symptoms; the Oswestry Disability Index
ranges from 0 to 100, with lower scores indicating less severe symptoms; the Stenosis Bothersomeness Index ranges from 0 to 24, with lower
scores indicating less severe symptoms; and the
Low Back Pain Bothersomeness Scale ranges from
0 to 6, with lower scores indicating less severe
symptoms.
Statistical Analysis

A sample size of 150 patients in each treatment
group for the randomized cohort was determined
as sufficient on the basis of a two-sided t-test with
a power of 0.85 to detect a 10-point difference in
the SF-36 bodily pain and physical function scores
or a similar effect size in the Oswestry Disability
Index. The sample size allowed for up to 20% of
the data to be missing but did not account for any
specific levels of nonadherence.
Initial analyses compared baseline characteristics of the patients between the randomized cohort and the observational cohort and between
the treatment groups of the combined randomized cohort and the observational cohort. The extent of missing data and the percentage of patients
undergoing surgery were calculated for each
scheduled follow-up. Baseline predictors of time
until surgical treatment in both cohorts (including
treatment crossovers) were determined by a stepwise proportional-hazards regression model with
an inclusion criterion of P<0.1 to enter and P>0.05
to exit. Predictors of missing follow-up visits at
1 year were determined by stepwise logistic regression with entry and exit criteria of P<0.1 and
P>0.05, respectively.
Primary analyses compared surgical and nonsurgical treatments using changes from baseline
at each follow-up time for SF-36 bodily pain and
physical function and for the Oswestry Disability
Index. The randomized cohort was initially analyzed on an intention-to-treat basis. However, because of the extent of crossover, subsequent analyn engl j med 356;22

ses combined the randomized cohort and the
observational cohort and were based on treatments
actually received. In these as-treated analyses, the
treatment indicator was a time-varying covariate,
allowing for variable times to surgery. Before the
time of surgery, all changes from baseline were
included in the estimates of the nonsurgical treatment effect. After surgery, subsequent changes in
outcomes were assigned to the surgical group with
follow-up measured from the date of surgery. The
randomized cohort and the observational cohort
were each analyzed to produce separate as-treated
estimates of treatment effect. These results were
compared with the use of a Wald test to simultaneously test all follow-up visit times for differences in estimated treatment effects between the
randomized and observational groups.24 Subsequent analyses combined the two cohorts.
To adjust for potential confounding effects,
baseline variables associated with missing data
or treatment received were included as covariates
in longitudinal regression models.24 A random
effect was specified to account for the correlation between the repeated measurements of individual patients. Computations were performed
with the use of SAS software (PROC MIXED for
continuous data with normal random effects and
PROC GENMOD for binary and non-normal secondary outcomes). Statistical significance was defined as P<0.05 on the basis of a two-sided hypothesis test (SAS software, version 9.1). Data for these
analyses were collected through October 3, 2006.

R e sult s
Overall, 607 of 892 eligible participants were enrolled in the SPORT (304 in the randomized cohort and 303 in the observational cohort). A total
of 601 patients (99%) completed at least one follow-up visit and were included in the analysis;
between 83% and 95% of enrollees supplied data
at each follow-up visit (Fig. 1).
In the randomized cohort, 159 patients were
assigned to surgery and 145 to nonsurgical treatment. Of those assigned to surgery, 57% underwent surgery by 1 year and 64% by 2 years. In
the group assigned to nonsurgical care, 44% underwent surgery by 1 year and 49% by 2 years. In
the observational cohort, 173 patients initially
chose surgery and 130 initially chose nonsurgical
care. Of those initially choosing surgery, 97% underwent surgery by 1 year, and one additional pa-
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1164 Patients were screened
272 Patients were ineligible
124 Were not surgical candidates
40 Had inadequate nonsurgical treatment
29 Had fracture, infection, or deformity
19 Had cancer
60 Had other reasons
892 Patients were eligible

285 Patients declined to participate

304 Were in the randomized
cohort

303 Were in the observational
cohort

159 Were assigned
to surgery

145 Were assigned to
nonsurgical treatment

173 Chose surgery

130 Chose nonsurgical
treatment

146 Were available at 6 wk
12 Missed the follow-up visit
1 Withdrew
0 Died

135 Were available at 6 wk
9 Missed the follow-up visit
1 Withdrew
0 Died

155 Were available at 6 wk
17 Missed the follow-up visit
1 Withdrew
0 Died

124 Were available at 6 wk
6 Missed the follow-up visit
0 Withdrew
0 Died

15 (9%) Underwent surgery

11 (8%) Underwent surgery

119 (69%) Underwent surgery

144 Were available at 3 mo
13 Missed the follow-up visit
2 Withdrew
0 Died

133 Were available at 3 mo
11 Missed the follow-up visit
1 Withdrew
0 Died

160 Were available at 3 mo
11 Missed the follow-up visit
2 Withdrew
0 Died

114 Were available at 3 mo
14 Missed the follow-up visit
2 Withdrew
0 Died

57 (36%) Underwent surgery

35 (24%) Underwent surgery

153 (88%) Underwent surgery

3 (2%) Underwent surgery

146 Were available at 6 mo
10 Missed the follow-up visit
2 Withdrew
1 Died

134 Were available at 6 mo
9 Missed the follow-up visit
1 Withdrew
1 Died

161 Were available at 6 mo
10 Missed the follow-up visit
2 Withdrew
0 Died

115 Were available at 6 mo
9 Missed the follow-up visit
5 Withdrew
1 Died

84 (53%) Underwent surgery

55 (38%) Underwent surgery

165 (95%) Underwent surgery

9 (7%) Underwent surgery

144 Were available at 1 yr
9 Missed the follow-up visit
4 Withdrew
2 Died

134 Were available at 1 yr
8 Missed the follow-up visit
2 Withdrew
1 Died

162 Were available at 1 yr
8 Missed the follow-up visit
3 Withdrew
0 Died

117 Were available at 1 yr
3 Missed the follow-up visit
8 Withdrew
2 Died

91 (57%) Underwent surgery

64 (44%) Underwent surgery

167 (97%) Underwent surgery

22 (17%) Underwent surgery

132 Were available at 2 yr
8 Missed the follow-up visit
11 Withdrew
2 Died
6 Visit pending

120 Were available at 2 yr
6 Missed the follow-up visit
5 Withdrew
5 Died
9 Visit pending

159 Were available at 2 yr
6 Missed the follow-up visit
5 Withdrew
3 Died

110 Were available at 2 yr
6 Missed the follow-up visit
11 Withdrew
3 Died

168 (97%) Underwent surgery

32 (25%) Underwent surgery

101 (64%) Underwent surgery

71 (49%) Underwent surgery

0 Underwent surgery

Figure 1. Exclusion, Enrollment, Randomization, and Follow-up of Trial Participants.
The values are cumulative over 2 years. For example, a total of two patients in the group assigned to surgery died during the 2-year
follow-up period.
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tient underwent surgery between 1 and 2 years
from the time of enrollment. Of those initially
choosing nonsurgical treatment, 17% underwent
surgery by 1 year and 25% by 2 years. In both cohorts combined, 372 patients underwent surgery
within the first 2 years and 235 received only nonsurgical treatment.
Patient Characteristics

Table 1 shows the baseline characteristics and
clinical findings of participants in the randomized and the observational cohorts. The cohorts
were remarkably similar; however, patients in the
observational cohort had more L4–L5 involvement, less involvement of L3–L4, and less lateral
recess stenosis.
Summary statistics for the combined cohorts
are also shown in Table 1 according to treatment
received; the mean age was 66 years. Eighty-five
percent of patients had neurogenic claudication,
and 77% had associated dermatomal pain radiation. Most of the degenerative slips and associated
stenoses were at L4–L5. On imaging, stenosis was
graded as severe in 60% of patients, and 35% had
multiple levels of stenosis.
At baseline, patients in the group undergoing
surgery from the combined randomized and observational cohorts were younger and more likely
to be receiving compensation (e.g., workers’ compensation or social security) than those receiving
nonsurgical treatment. They had worse pain, function, disability, and symptoms than patients in
the nonsurgical group. Patients in the surgery
group were more dissatisfied with their symptoms and at enrollment more often rated their
symptoms as worsening. This observation highlights the need to control for baseline differences
in the adjusted models. The final model controlled
for the following covariates, selected as described
in the Methods section: age, sex, work status, depression, osteoporosis, joint problems, duration of
current symptoms, reflex deficit, number of moderate or severe stenotic levels, baseline score (for
the SF-36, the Oswestry Disability Index, and the
Stenosis Bothersomeness Index), and the center
where the patient was treated. SF-36 and the Oswestry Disability Index scores were also adjusted
for the baseline Stenosis Bothersomeness Index
score.
Lateral radiographs obtained with the patient
in a neutral standing position were available for
independent review for 169 patients. The percentage of slip as measured by the method of Morn engl j med 356;22

gan and King25 ranged from 1 to 37% (median,
15%; interquartile range, 10 to 21%). Eighty-six
percent of patients had grade 1 slip and 14% had
grade 2.
Nonsurgical Treatments

Nonsurgical treatments used during the SPORT
included physical therapy (42%), epidural steroid
injections (45%), nonsteroidal antiinflammatory
drugs (51%), and opioids (34%). Nonsurgical treatments were similar in the randomized cohort and
the observational cohort, though more patients
in the randomized cohort reported visits to a surgeon (44% vs. 34%, P = 0.04), receiving injections
(49% vs. 37%, P = 0.02), and narcotics use (40% vs.
26%, P = 0.007).
Surgical Treatment and Complications

The median surgical time was 199 minutes, with
a mean blood loss of 589 ml (Table 2). There were
no significant differences between the cohorts in
rates of intraoperative blood replacement, but there
was a difference in the postoperative transfusion
rates (16% in the randomized cohort vs. 26% in
the observational cohort, P = 0.04). The most common surgical complication was dural tear (10%).
The 2-year reoperation rate was 12%.
Main Treatment effects

The intention-to-treat analysis of the randomized
cohort showed no statistically significant effects
for the primary outcomes, on the basis of a global
hypothesis test for differences in mean changes
from baseline between the treatment groups including all time periods. Treatment effects at
2 years were 1.5 for SF-36 bodily pain (95% confidence interval [CI], –4.2 to 7.3; P = 0.52), 1.9 for
physical function (95% CI, –3.7 to 7.5; P = 0.71),
and 2.2 for the Oswestry Disability Index (95% CI,
–2.3 to 6.8; P = 0.68).
As-treated effects for the combined cohorts
were statistically significant in favor of surgery for
all primary and secondary outcomes (Table 3 and
Fig. 2). Treatment effects were stable for 2 years
and were significant for all time periods, with
treatment effects at 2 years of 18.1 for SF-36
bodily pain (95% CI, 14.5 to 21.7), 18.3 for physical
function (95% CI, 14.6 to 21.9), and −16.7 for the
Oswestry Disability Index (95% CI, −19.5 to −13.9).
The results of the intention-to-treat and the astreated analyses of the randomized and the observational cohorts are compared in Figure 2. The
as-treated treatment effects at 2 years were nearly

www.nejm.org

may 31, 2007

2261

The New England Journal of Medicine
Downloaded from nejm.org at THOMAS JEFFERSON UNIVERSITY on June 19, 2012. For personal use only. No other uses without permission.
Copyright © 2007 Massachusetts Medical Society. All rights reserved.

n e w e ng l a n d j o u r na l

The

of

m e dic i n e

Table 1. Characteristics of the Patients According to Study Cohort at Baseline.*
Randomized Observational
Cohort
Cohort
P
(N = 301)
(N = 300)
Value

Characteristic

Surgical
Treatment
(N = 368)†

Nonsurgical
Treatment
P
(N = 233)† Value

Age — yr

66.0±10.0

66.1±10.6

0.86

64.7±10.1

68.2±10.3 <0.001

Female sex — no. (%)

200 (66)

212 (71)

0.30

255 (69)

157 (67)

0.69

Non-Hispanic

292 (97)

295 (98)

0.42

359 (98)

228 (98)

0.97

White

259 (86)

247 (82)

0.26

316 (86)

190 (82)

0.19

Black

29 (10)

32 (11)

0.78

30 (8)

31 (13)

0.06

Any college education — no. (%)

201 (67)

199 (66)

0.98

247 (67)

153 (66)

0.78

Married — no. (%)

198 (66)

198 (66)

0.98

249 (68)

147 (63)

Race or ethnic group — no. (%)‡

Work status — no. (%)

0.42

Working full- or part-time

116 (39)

102 (34)

133 (36)

21 (7)

30 (10)

33 (9)

18 (8)

Retired

129 (43)

128 (43)

156 (42)

101 (43)

Other

46 (12)

29 (12)

Disabled

0.29
0.96

85 (36)

35 (12)

40 (13)

Compensation — no. (%)§

21 (7)

20 (7)

0.99

34 (9)

7 (3)

0.005

Body-mass index¶

29.1±5.7

29.2±6.7

0.91

29.4±6.5

28.8±5.7

0.22

Current smoker — no. (%)

23 (8)

28 (9)

0.55

34 (9)

17 (7)

0.49

Coexisting conditions — no. (%)
Hypertension

141 (47)

134 (45)

0.65

164 (45)

111 (48)

0.51

Diabetes

39 (13)

41 (14)

0.89

48 (13)

32 (14)

0.90

Osteoporosis

33 (11)

36 (12)

0.79

40 (11)

29 (12)

0.65

Heart problem

61 (20)

61 (20)

0.94

65 (18)

57 (24)

0.055

Stomach problem

64 (21)

69 (23)

0.68

79 (21)

54 (23)

0.70

Bowel or intestinal problem

17 (6)

26 (9)

0.20

30 (8)

13 (6)

0.30

Depression

56 (19)

42 (14)

0.16

63 (17)

35 (15)

0.57

Joint problem

175 (58)

169 (56)

0.72

202 (55)

142 (61)

0.17

Other‖

121 (40)

113 (38)

0.58

146 (40)

88 (38)

0.70

185 (61)

176 (59)

0.54

227 (62)

134 (58)

0.35

Symptom duration >6 mo — no. (%)
SF-36 scores**
Bodily pain

30.7±16.4

31.7±17.5

0.44

29.2±16.8

34.4±16.7 <0.001

Physical function

34.4±21.5

34.3±23.3

0.98

30.5±20.5

40.3±23.9 <0.001

Mental component summary

49.9±11.9

50.5±11.2

0.53

49.5±11.6

51.3±11.3

Oswestry Disability Index††

41.8±16.5

41.3±19.1

0.72

45.0±16.6

36.2±18.5 <0.001

Stenosis Frequency Index‡‡

14.2±5.5

13.8±5.7

0.36

14.8±5.5

12.6±5.4

<0.001

Stenosis Bothersomeness Index§§

14.8±5.6

14.6±5.6

0.79

15.6±5.5

13.3±5.4

<0.001

Low Back Pain Bothersomeness Scale¶¶
Very dissatisfied with symptoms — no. (%)

4.3±1.8

4.3±1.8

0.99

4.4±1.8

4.0±1.9

0.01

203 (67)

213 (71)

0.39

287 (78)

129 (55)

<0.001

17 (6)

21 (7)

17 (5)

21 (9)

Self-assessment of health trend — no. (%)‖‖
Problem getting better

0.73
100 (33)

94 (31)

89 (24)

105 (45)

Problem getting worse

179 (59)

182 (61)

258 (70)

103 (44)

Treatment preference at baseline — no. (%)***
Probably prefer nonsurgical treatment

<0.001

<0.001

44 (15)

83 (28)

32 (9)

95 (41)

71 (24)

37 (12)

40 (11)

68 (29)

117 (39)

20 (7)

83 (23)

54 (23)

Probably prefer surgery

30 (10)

31 (10)

51 (14)

10 (4)

Definitely prefer surgery

38 (13)

129 (43)

162 (44)

5 (2)

Not sure

2262

<0.001

Problem staying about the same

Definitely prefer nonsurgical treatment

0.06
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Table 1. (Continued.)
Randomized Observational
Cohort
Cohort
P
(N = 301)
(N = 300)
Value

Characteristic
Pseudoclaudication — no. (%)

Surgical
Treatment
(N = 368)†

Nonsurgical
Treatment
P
(N = 233)† Value

259 (86)

252 (84)

0.56

319 (87)

192 (82)

0.19

44 (15)

41 (14)

0.83

48 (13)

37 (16)

0.39

Dermatomal pain radiation — no. (%)

239 (79)

229 (76)

0.42

288 (78)

180 (77)

0.85

Any neurologic deficit — no. (%)

142 (47)

152 (51)

0.44

185 (50)

109 (47)

0.45

Asymmetric reflex depression

53 (18)

40 (13)

0.18

65 (18)

28 (12)

0.08

Asymmetric sensory decrease

79 (26)

90 (30)

0.35

108 (29)

61 (26)

0.45

Asymmetric motor weakness

74 (25)

72 (24)

0.94

87 (24)

59 (25)

Straight-leg–raising test or femoral-tension
sign — no. (%)

Listhesis level — no. (%)

0.17

0.71
0.69

L3–L4

34 (11)

23 (8)

33 (9)

24 (10)

L4–L5

267 (89)

277 (92)

335 (91)

209 (90)

Stenosis level — no. (%)
L2–L3

31 (10)

22 (7)

0.26

33 (9)

20 (9)

L3–L4

136 (45)

100 (33)

0.004

145 (39)

91 (39)

1.00

L4–L5

285 (95)

295 (98)

0.03

357 (97)

223 (96)

0.54

L5–S1

27 (9)

30 (10)

0.77

29 (8)

28 (12)

0.12

No. of moderate or severe stenotic levels —
no. (%)

0.10

0.99

0.14

0

7 (2)

16 (5)

9 (2)

14 (6)

1

179 (59)

191 (64)

231 (63)

139 (60)

2

96 (32)

76 (25)

104 (28)

68 (29)

≥3

19 (6)

17 (6)

24 (7)

12 (5)

Central

277 (92)

272 (91)

0.65

341 (93)

208 (89)

0.20

Lateral recess

286 (95)

260 (87)

<0.001

338 (92)

208 (89)

0.36

Neuroforamen

123 (41)

120 (40)

0.89

152 (41)

91 (39)

0.64

9 (2)

14 (6)

Stenosis location — no. (%)

Stenosis severity — no. (%)
Mild

0.08
7 (2)

16 (5)

0.08

Moderate

116 (39)

99 (33)

131 (36)

84 (36)

Severe

178 (59)

185 (62)

228 (62)

135 (58)

26 (9)

21 (7)

35 (10)

12 (5)

Instability — no. (%)†††

0.55

0.07

*
†

Plus–minus values are means ±SD.
Patients in the two cohorts combined were classified according to whether they received surgical treatment or only
nonsurgical treatment during the first 2 years of enrollment.
‡ Race or ethnic group was self-assessed. Whites and blacks could be either Hispanic or non-Hispanic.
§ This category includes patients who were receiving or had applications pending for workers’ compensation, Social
Security compensation, or other compensation.
¶ The body-mass index is the weight in kilograms divided by the square of the height in meters.
‖ Other problems included those related to stroke, cancer, lung disease, fibromyalgia, chronic fatigue syndrome, posttraumatic stress disorder, alcohol abuse, drug dependency, liver disease, kidney disease, vascular disease, neurologic
disease, migraine, or anxiety.
** The SF-36 scores range from 0 to 100, with higher scores indicating less severe symptoms.
†† The Oswestry Disability Index ranges from 0 to 100, with lower scores indicating less severe symptoms.
‡‡ The Stenosis Frequency Index ranges from 0 to 24, with lower scores indicating less severe symptoms.
§§ The Stenosis Bothersomeness Index ranges from 0 to 24, with lower scores indicating less severe symptoms.
¶¶ The Low Back Pain Bothersomeness Scale ranges from 0 to 6, with lower scores indicating less severe symptoms.
‖‖ Data were not available for eight patients.
*** Data were not available for one patient.
††† Instability is defined as a change of more than 10 degrees of angulation or more than 4 mm of translation of the vertebrae between flexion and extension of the spine.
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Table 2. Surgical Treatments and Complications.*

Variable

Randomized
Cohort
(N = 172)

Observational
Cohort
(N = 200)

10 (6)

10 (5)

Specific procedure — no. (%)†

P Value
0.92

Decompression only
Fusion without instrumentation
Fusion with instrumentation‡
Multilevel fusion — no. (%)

35 (21)

43 (21)

123 (73)

147 (74)

46 (27)

40 (20)

0.13

Decompression level — no. (%)
L2–L3

25 (15)

17 (8)

0.08

L3–L4

92 (54)

84 (42)

0.02

L4–L5

165 (98)

190 (95)

0.34

L5–S1

60 (36)

47 (24)

0.01

No. of levels decompressed — no. of patients (%)

0.01

0

1 (1)

2 (1)

1

56 (33)

98 (49)

2

65 (38)

65 (32)

≥3

47 (28)

35 (18)

Operation time — min

210.5±81.7

202.7±85.8

0.37

Blood loss — ml

570.0±425.7

606.2±511.2

0.47

60 (36)

67 (34)

0.71

Blood replacement — no. (%)
Intraoperative replacement
Postoperative transfusion
Length of hospital stay — days

27 (16)

51 (26)

0.04

6.9±28.7

4.8±3.3

0.30

19 (11)

18 (9)

0.59

Intraoperative complications — no. (%)§
Dural tear or cerebrospinal fluid leak
Vascular injury

1 (1)

0

0.93

Other

3 (2)

6 (3)

0.67

identical in the randomized and the observational
cohorts. For SF-36 bodily pain, the effect was 17.8
(95% CI, 12.5 to 23.0) in the randomized cohort
as compared with 18.5 (95% CI, 13.4 to 23.6) in
the observational cohort; for SF-36 physical function, the effect was 16.7 (95% CI, 11.4 to 22.1)
in the randomized cohort as compared with 19.9
(95% CI, 14.8 to 24.9) in the observational cohort;
and for the Oswestry Disability Index, the effect
was −15.9 (95% CI, −20.2 to −11.7) in the randomized cohort as compared with −17.7 (95% CI, −21.6
to −13.7) in the observational cohort. The global
hypothesis test comparing the treatment effects
in the randomized and the observational cohorts
over all time periods revealed no significant difference between the cohorts: P = 0.29 for SF-36
bodily pain, P = 0.28 for SF-36 physical function,
and P = 0.97 for the Oswestry Disability Index.
2264
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Subgroup Analyses

Models fitted for selected subgroups were examined for evidence of modification of treatment
efficacy. Participants less than 65 years old at
baseline had larger treatment effects in favor of
surgery at 3 months (21.3 vs. 14.6 for bodily pain,
P = 0.02) but not at 1 or 2 years. The treatment
effect for a degenerative spondylolisthesis level of
L3–L4 was larger than that for a level of L4–L5
(33.1 vs. 16.8 for SF-36 bodily pain, P = 0.01) at
2 years but not at 3 months or 1 year. Participants
with no more than a high-school education had
smaller treatment effects for surgery at 3 months
(12.8 vs. 20.5 for SF-36 bodily pain, P = 0.02) and
2 years (11.5 vs. 21.6 for SF-36 bodily pain,
P = 0.01). Other subgroups (defined according to
sex, smoking history, severity of symptoms at baseline, duration of symptoms, treatment preference,
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Table 2. (Continued.)
Randomized
Cohort
(N = 172)

Variable

Observational
Cohort
(N = 200)

P Value

Postoperative complications and events — no. (%)¶
Nerve-root injury

1 (1)

0

0.93

Wound dehiscence

0

1 (1)

0.93

Wound hematoma

0

1 (1)

0.93

8 (5)

3 (2)

0.12

21 (12)

14 (7)

0.10

Wound infection
Other
Death within 3 mo after surgery — no. (%)
Additional spine surgeries within 1 yr — no. (%)‖**
Recurrent stenosis or progressive listhesis
Pseudarthrosis or fusion exploration

1 (1)

1 (1)

0.55

13 (8)

11 (6)

0.40

1 (1)

1 (1)

0

Complication

1 (1)

11 (6)

New condition

7 (4)

1 (1)

Additional spine surgeries within 2 yr — no. (%)‖

1 (0.5)

18 (11)

23 (12)

Recurrent stenosis or progressive listhesis

5 (3)

5 (2)

Pseudarthrosis or fusion exploration

0

3 (2)

Complication
New condition‖

13 (8)

11 (6)

1 (1)

4 (2)

0.84

* A total of 172 patients in the randomized cohort and 200 patients in the observational cohort underwent surgery within 2 years after enrollment. Information about the surgery was available for 169 patients from the randomized cohort
and 200 from the observational cohort. Plus–minus values are means ±SD.
† Data on specific procedures were available for 168 patients in the randomized cohort and 200 patients in the observational cohort.
‡ All 270 patients undergoing fusion with instrumentation had pedicle screws; 46 underwent additional interbody fusion.
§ No cases were reported of aspiration into the respiratory tract, nerve-root injury, or operation at the wrong level.
¶ Complications or events occurring up to 8 weeks after surgery are listed. There were no reported cases of bone-graft
complication, cerebrospinal fluid leak, paralysis, cauda equina injury, or pseudarthrosis.
‖ The postsurgical reoperation rates are Kaplan–Meier estimates.
** One new stenosis occurred in the randomized cohort, and two new herniations and two new stenoses occurred in the
observational cohort.

number of stenotic levels, severity of stenosis on
imaging, number of coexisting conditions, and
baseline SF-36 mental component summary score)
did not show significant effect modification.
These results should be considered cautiously, because the study was not designed or powered to
examine subgroup differences.

Dis cus sion
In patients with image-confirmed degenerative
spondylolisthesis and symptoms persisting for at
least 12 weeks, the intention-to-treat analysis
found no significant advantage for surgery over
nonsurgical care, but the analysis was severely
limited by treatment crossover. As-treated analyses showed that surgery was superior to nonsurgical treatment in relieving symptoms and imn engl j med 356;22

proving function. This treatment effect was seen
as early as at the 6-week follow-up and persisted
over 2 years. The nonsurgical-treatment group
showed only moderate improvement over time.
The smaller treatment effect for surgery seen in
less-educated subjects is intriguing but unexplained and may be a chance finding in a post hoc
subgroup.
The randomized and observational cohorts
were remarkably similar at baseline. The only
significant differences were small ones in level
and location of stenosis on baseline imaging. The
cohorts also had similar outcomes, with no significant differences between the treatment effects
in the as-treated analyses. These similarities support the validity of the combined analysis presented here.
There was little evidence of harm from either
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21.5±1.1
−20.8±0.9

Oswestry Disability Index¶
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90.8

Very or somewhat satisfied
with care (%)
19.9

68.3

24.0

17.8 (14.9 to 20.6)

31.5±1.2
29.0±1.2

57.7 (51.8 to 63.5)

22.5 (16.4 to 28.5)

45.6 (39.1 to 52.1)

−1.2 (−1.5 to −0.9)

−2.1 (−2.5 to −1.8)

−6.9 (−8.0 to −5.9)

77.2

90.8

73.2

−2.4±0.1

−3.1±0.1

−9.5±0.4

−14.6 (−16.8 to −12.4) −25.4±1.0

13.9 (11.1 to 16.8)

24.8

68.2

26.8

−1.1±0.1

−1.4±0.1

−4.0±0.4

−7.5±1.1

9.6±1.3

12.7±1.3

52.4 (45.3 to 59.6)

22.6 (15.6 to 29.6)

46.4 (39.0 to 53.9)

−1.4 (−1.6 to −1.1)

−1.6 (−1.9 to −1.3)

−5.5 (−6.5 to −4.5)

−17.9 (−20.5 to −15.3)

19.4 (16.1 to 22.7)

18.8 (15.5 to 22.1)

Treatment
Effect of Surgery
(95% CI)‡

74.1

89.2

68.8

−2.2±0.1

−2.9±0.1

−8.9±0.4

−24.2±1.0

26.6±1.3

29.9±1.2

Surgery
(N = 324)

2 Yr

24.1

67.3

32.2

−1.2±0.1

−1.4±0.1

−4.0±0.4

−7.5±1.2

8.3±1.5

11.7±1.5

Nonsurgical
Treatment
(N = 187)

50.0 (42.2 to 57.9)

21.9 (13.9 to 29.9)

36.6 (28.0 to 45.1)

−1.0 (−1.3 to −0.7)

−1.5 (−1.8 to −1.1)

−4.9 (−6.0 to −3.8)

−16.7 (−19.5 to −13.9)

18.3 (14.6 to 21.9)

18.1 (14.5 to 21.7)

Treatment
Effect of Surgery
(95% CI)‡

of

* Scores are adjusted for age, sex, work status, depression, osteoporosis, joint problems, duration of current symptoms, reflex deficit, number of moderate or severe stenotic levels, baseline
scores (for the SF-36, Oswestry Disability Index, and Stenosis Bothersomeness Index), and the center where the patient was treated. Plus–minus values are means ±SE and represent
changes from baseline. Percentages represent the proportion of patients giving positive responses at each follow-up examination.
† For secondary outcomes, the total number of patients was 263.
‡ The global P value based on a Wald test assessing all time points simultaneously is less than 0.001 for all measures.
§ The SF-36 scores range from 0 to 100, with higher scores indicating less severe symptoms.
¶ The Oswestry Disability Index ranges from 0 to 100, with lower scores indicating less severe symptoms.
‖ The Stenosis Bothersomeness Index ranges from 0 to 24, with lower scores indicating less severe symptoms.
** The Leg Pain and the Low Back Pain Bothersomeness Scales range from 0 to 6, with lower scores indicating less severe symptoms.

77.5

69.6

Very or somewhat satisfied
with symptoms (%)

−1.0±0.1

−1.1±0.1

−3.3±0.3

−6.2±0.9

7.6±1.2

10.3±1.1

Surgery
(N = 286)

1 Yr
Nonsurgical
Treatment
(N = 234)

Treatment
Effect of Surgery
(95% CI)‡

3 Mo
Nonsurgical
Treatment
(N = 320)

n e w e ng l a n d j o u r na l

Self-rated major improvement
in progress (%)

−2.2±0.1

−3.2±0.1

Leg Pain Bothersomeness
Scale**

Low Back Pain Bothersome
ness Scale**

−10.2±0.5

Stenosis Bothersomeness
Index‖

Secondary outcomes

28.1±1.1

SF-36 bodily pain§

Surgery
(N = 385)†

SF-36 physical function§

Primary outcomes

Outcome

Table 3. Change Scores and Treatment Effects for Primary and Secondary Outcomes in the Randomized and Observational Cohorts Combined, According to Treatment Received.*
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treatment. Often patients fear they will get worse
without surgery, but the patients receiving nonsurgical treatment, on average, showed moderate
improvement in all outcomes. No patients undergoing surgical or nonsurgical treatment had cauda
equina syndrome; 89% of surgical patients had
no operative complications.
The characteristics of the participants in the
SPORT were similar to those in previous studies
of degenerative spondylolisthesis and mixed cohorts of patients with stenosis. The mean age of
66 years was similar to that in the cohorts reported by Herkowitz and Kurz8 (63.5 years),
Fischgrund et al.7 (67 years), the Maine Lumbar
Spine Study (MLSS)3 (66 years), Yukawa et al.26
(63 years), and Malmivaara et al.5 (63 years). At
enrollment, 60% of the SPORT participants reported having had symptoms for more than
6 months, as did 60% of the participants in the
MLSS. Baseline functional status in the SPORT
was similar to that in the MLSS (mean SF-36
physical function scores, 34 and 35, respectively)
and in the randomized trial by Malmivaara et al.
(mean Oswestry Disability Index scores, 41.5 and
35.0, respectively).
The surgical outcomes in the SPORT were generally similar to those in previous surgical series.
Herkowitz and Kurz8 reported absolute improvements of 33% for back pain and 55% for leg pain
(6-point scales) at 3 years, similar to the changes
of 31% and 41%, respectively (7-point scales), seen
in the SPORT at 2 years. Also, the improvement
at 1 year in the patients in the SPORT who were
undergoing surgery for degenerative spondylolisthesis was similar to the outcomes of surgery in
the MLSS mixed-stenosis (those with and those
without degenerative spondylolisthesis) cohort.
The improvement in the SF-36 bodily pain score
was 32 in the SPORT and 43 in the MLSS, and
the improvement in the SF-36 physical function
score was 29 in the SPORT and 27 in the MLSS.3
The nonsurgical outcomes in the SPORT were
similar to those in the study by Malmivaara et al.5
and in the MLSS.3 Malmivaara et al. reported
absolute improvements in back pain at 2 years of
18% on an 11-point scale, as compared with 17%
on a 7-point scale in the SPORT, and an improvement in leg pain of 16%, as compared with 17%
in the SPORT. Similarly, at 1 year the MLSS reported an improvement of 12.0 points in SF-36
bodily pain, as compared with 12.7 in the SPORT.
The nonsurgical functional outcomes, however,
n engl j med 356;22

were better in the SPORT than in these previous
studies. SF-36 physical function improved by 9.6
points in the SPORT nonsurgical group, as compared with 1.0 point in the MLSS, and the Oswestry Disability Index improved by −7.5 points
in the SPORT, as compared with −4.5 points in
the study by Malmivaara et al. The somewhat
greater improvement in the SPORT may be related
to the nonsurgical treatments received. The SPORT
participants had higher rates of epidural steroid
injections than did the MLSS participants (44%
vs. 18%), similar rates of physical therapy, and
much lower use of activity restriction (16% vs.
29%) and transcutaneous electrical nerve stimulation (2% vs. 14%). Differences in nonsurgical
outcomes might also be due to differences in the
underlying disease process in patients with degenerative spondylolisthesis as compared with a
mixed stenosis population in the study by Malmivaara et al. and in the MLSS.
We can directly compare estimates of treatment
effect in the SPORT with those in the MLSS and
the study by Malmivaara et al. The estimated 1-year
treatment effects for surgery in the SPORT were
smaller than those in the MLSS (18.8 vs. 30.4
points for SF-36 bodily pain, and 19.4 vs. 25.5
points for SF-36 physical function). However, the
MLSS did not adjust treatment effects for baseline differences between the treatment groups,
which probably explains these discrepancies. The
estimated 1-year treatment effects were similar
in the SPORT and in the study by Malmivaara et al.
(Oswestry Disability Index, −17.9 vs. −11.3, respectively; leg pain, 23% [7-point scale] vs. 15%
[11-point scale], respectively; and back pain, 20%
[7-point scale] vs. 21% [11-point scale], respectively.
The 1-year rate of reoperation for recurrent
stenosis or spondylolisthesis was 0.6%, less than
the rates reported by Malmivaara et al. (2%) and
the MLSS (1.2%). The reoperation rate increased
to 3% at 2 years. The perioperative mortality rate
was 0.6%, which is less than the 1.3% seen in
Medicare patients after fusion surgery for spondylolisthesis.27 The 2-year mortality rate was similar in both treatment groups and less than actuarial projections.
A limitation of this study is the marked degree of nonadherence to randomized treatment.
The protocol stipulated that patients assigned to
surgery have their surgery within 3 to 6 months
after enrollment, a period thought to be appro-
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A Randomized Cohort — SF-36 Bodily Pain

B Observational Cohort — SF-36 Bodily Pain
80

Adjusted Mean Score

80

Adjusted Mean Score

m e dic i n e

Nonsurgical treatment — as treated
Nonsurgical treatment — intention-to-treat
(randomized cohort only)

Surgery — as treated
Surgery — intention-to-treat
(randomized cohort only)

60

40

20
0

of

60

40

20

0

3

6

12

0

24

0

3

6

12

Months

C Randomized Cohort — SF-36 Physical Function

D Observational Cohort — SF-36 Physical Function
80

Adjusted Mean Score

Adjusted Mean Score

80

60

40

20
0

60

40

20

0

3

6

12

0

24

0

3

6

12

Months

F Observational Cohort — Oswestry Disability Index
60

Adjusted Mean Score

Adjusted Mean Score

60

40

20

0

3

6

12

24

40

20

0

0

3

6

12

Months

24

Months

AUTHOR: Weinstein

ICM
REG F

2268

24

Months

E Randomized Cohort — Oswestry Disability Index

0

24

Months

RETAKE

FIGURE: 2 of 2

1st
2nd
3rd

nCASE
engl j med 356;22

www.nejm.org mayRevised
31, 2007
Line
4-C
SIZE
ARTIST:
ts
The New England JournalH/T
of Medicine
H/T
33p9
Enon
Combo
Downloaded from nejm.org at THOMAS JEFFERSON UNIVERSITY on June 19, 2012. For personal use only. No other uses without permission.
EMail

AUTHOR,
PLEASE
NOTE:
Copyright © 2007 Massachusetts
Medical
Society.
All rights reserved.
Figure has been redrawn and type has been reset.

Treatment of Lumbar Degener ative Spondylolisthesis

Figure 2 (facing page). Intention-to-Treat and As-Treated Results over Time for the Primary Outcome Measures of SF-36 Bodily Pain (Panels A and B), SF-36
Physical Function (Panels C and D), and the Oswestry
Disability Index (Panels E and F).
SF-36 bodily pain and physical function scores range
from 0 to 100, with higher scores indicating less severe
symptoms. The Oswestry Disability Index ranges from
0 to 100, with lower scores indicating less severe
symptoms. The horizontal dashed line in each of the
four SF-36 graphs represents the age- and sex-adjusted
norms. I bars represent the 95% confidence intervals.
The floating symbols at 0 months represent the observed mean scores for each treatment group, whereas
the plotline at 0 months originates from the overall
mean as used in the adjusted analyses.

priate in the clinical experience of the investigators. Although patients consented to this protocol, as in all clinical trials this consent could be
changed at the request of the patient, and many
chose to do so. This reduced the power of the
intention-to-treat analysis to demonstrate a treatment effect. Although the as-treated analysis lost
the strong protection from confounding conferred
by randomization, these analyses were carefully
controlled for important covariates and yielded
results similar to previous studies.
Another limitation is the heterogeneity of the
treatment interventions. The choice of nonsurgical therapies was at the discretion of the treating
physician and the patient. However, with limited
evidence regarding efficacy for most nonsurgical
treatments for degenerative spondylolisthesis,
creating a fixed protocol for nonsurgical treatment was neither clinically feasible nor generalizable. The nonsurgical treatments used were
consistent with published guidelines.28,29 Similarly, the surgeries performed varied in terms of
the presence, method, and extent of spinal fusion
accompanying the decompression. We cannot
make direct conclusions regarding the comparison between the effect of surgery and any specific
nonsurgical treatment, nor do we directly compare the efficacy of nonsurgical treatment with
one specific surgical technique.
The magnitudes of the mean changes reported
here after surgery for degenerative spondylolisthesis are less than those reported for patients in
a SPORT observational cohort undergoing surgery
for intervertebral disk herniation. The mean change
scores after 2 years were as follows: SF-36 bodily
n engl j med 356;22

pain, 29.9 for degenerative spondylolisthesis versus 42.6 for intervertebral disk herniation; SF-36
physical function, 26.7 for degenerative spondylolisthesis versus 43.9 for intervertebral disk herniation; Oswestry Disability Index, −24.2 for
degenerative spondylolisthesis versus 37.6 for intervertebral disk herniation.9,10 However, the treatment effects for surgery in the degenerativespondylolisthesis group were larger than those
in the study of intervertebral disk herniation (18.4
for bodily pain in the degenerative-spondylolisthesis group vs. 10.2 in the intervertebral-disk-herniation study) because of dramatic improvements
in the nonsurgical group with intervertebral disk
herniation not seen in the degenerative-spondylolisthesis group.
In these nonrandomized comparisons with
careful control of potentially confounding baseline factors, patients with persistent neurogenic
claudication from degenerative spondylolisthesis
treated surgically showed substantially greater
improvement in pain and function, as well as
satisfaction, for 2 years. Characteristics of the
patients and treatment outcomes were similar in
the randomized and observational cohorts.
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Treatment of Lumbar Degener ative Spondylolisthesis
APPENDIX
In addition to the authors, the following investigators participated in the Spine Patient Outcomes Research Trial (institutions are in order
from highest to lowest enrollment): Dartmouth Medical School, Hanover, NH — J. Forman, B. Butler-Schmidt, J.J. Hebb, P. Bernini. R. Hazard,
P. Ball, C. Murray, M. Splaine, D. Sengupta, H. Schmidek, R. Rose, C. Olson, P. McDonough, H. Magnasdottir; William Beaumont Hospital,
Royal Oak, MI — G. Bradley, M. Lurie, L. Kurz, J. Fischgrund, D. Montgomery, E. Truumees; Rothman Institute at Thomas Jefferson Hospital, Philadelphia — C. Simon, T. Conliffe; Hospital for Special Surgery, New York — B. Green, J. Farmer, H. Sandhu; Nebraska Foundation for Spinal Research,
Omaha — N. Fullmer, A.M. Fredericks, R. Woodward, J. Fuller, E. Phillips, J. McClellan, P. Bowman, T. Burd; Emory University–Emory Clinic,
Atlanta — S. Boden, S. Lashley, H. Levy, D. Hubbell, M. Schaufele, J. Rhee, S.T. Yoon, S. Dreyer, J. Heller; Washington University, St. Louis — G.
Stobbs, K. Bridwell, A. Margherita, K.D. Riew, B. Taylor, J. Metzler; University Hospitals of Cleveland and Case Western Reserve University, Cleveland
— C. Furey, K. Higgins, J.X. Yoo, E.B. Marsolais, H. Bohlman; Hospital for Joint Diseases, New York — A. Lee, J. Bendo, J. Goldstein, J. Spivak,
R. Perry, R. Schoenfeldt, R. Moskovich, J. Dryer; Kaiser Permanente, Oakland, CA — H. Goldberg, P. Malone, F. Massimino; University of California,
San Francisco, San Francisco — P. Malone, S. Berven, T. Smith; Rush–Presbyterian–St. Luke’s Medical Center, Chicago — G. Andersson, H. An, M.
Hickey, E. Goldberg, F. Philips; Maine Spine and Rehabilitation, Scarborough — R. Keller, L. Thibodeau, J. Florman.
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